PCSK9 Inhibitor [EPC]

25752 reported adverse events

Drugs of this class: ALIROCUMAB EVOLOCUMAB

These side effects are most commonly reported by patients taking drugs of the PCSK9 Inhibitor [EPC] class:

# Side effect Count
0 DEVICE DIFFICULT TO USE 33307
1 DRUG DOSE OMISSION BY DEVICE 25089
2 WRONG TECHNIQUE IN PRODUCT USAGE PROCESS 22769
3 ACCIDENTAL EXPOSURE TO PRODUCT 17230
4 INJECTION SITE PAIN 12599
5 MYALGIA 7078
6 PRODUCT STORAGE ERROR 7071
7 BACK PAIN 6128
8 INJECTION SITE BRUISING 5820
9 DRUG DOSE OMISSION 5254
See all common reactions for PCSK9 Inhibitor [EPC]

Drugs of the PCSK9 Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 LOW DENSITY LIPOPROTEIN DECREASED 851 0.6006
1 INCORRECT DISPOSAL OF PRODUCT 1746 0.5371
2 DEVICE DIFFICULT TO USE 33307 0.5027
3 LOW DENSITY LIPOPROTEIN ABNORMAL 235 0.3834
4 PRODUCT COMMUNICATION ISSUE 2939 0.3328
5 INTERCEPTED PRODUCT ADMINISTRATION ERROR 2523 0.3287
6 DRUG DOSE OMISSION BY DEVICE 25089 0.3201
7 BLOOD CHOLESTEROL DECREASED 546 0.2929
8 PRODUCT KNOWLEDGE DEFICIT 205 0.2621
9 INJECTION SITE INDENTATION 463 0.2136
See all enriched reactions for PCSK9 Inhibitor [EPC]